Epidermolytic palmoplantar keratoderma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2199OMIM:144200Q82.8
Who is this for?
Show terms as
5Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Epidermolytic palmoplantar keratoderma (EPPK), also known as Vörner palmoplantar keratoderma or keratosis palmoplantaris cum degeneratione granulosa, is a hereditary skin disorder characterized by diffuse, thick, yellow hyperkeratosis (thickening of the skin) affecting the palms of the hands and soles of the feet. It is the most common form of diffuse palmoplantar keratoderma. Symptoms typically appear in the first months of life, with well-demarcated thickening of the skin on the palms and soles that may be accompanied by a red border at the margins. The thickened skin can develop painful fissures (cracks), and hyperhidrosis (excessive sweating) of the affected areas is common, which may lead to secondary bacterial or fungal infections and associated malodor. Histologically, the condition is distinguished by epidermolytic hyperkeratosis, a characteristic pattern of degeneration in the upper layers of the epidermis. EPPK is caused by mutations in the KRT9 gene (keratin 9), which encodes a keratin protein expressed specifically in the suprabasal epidermis of palms and soles. Less commonly, mutations in KRT1 (keratin 1) have been associated with this condition, sometimes with mild involvement of skin beyond the palms and soles. The disease follows an autosomal dominant inheritance pattern, meaning a single copy of the altered gene is sufficient to cause the disorder. There is currently no cure for epidermolytic palmoplantar keratoderma. Treatment is symptomatic and focuses on managing the thickened skin. Topical keratolytic agents such as salicylic acid, urea-based creams, and topical retinoids are commonly used to soften and reduce the hyperkeratosis. Mechanical debridement (careful removal of thickened skin) may also be helpful. Oral retinoids such as acitretin may be considered in more severe cases but require careful monitoring due to potential side effects. Management of hyperhidrosis and prevention of secondary infections are also important aspects of care. Regular follow-up with a dermatologist experienced in genodermatoses is recommended.

Also known as:

Clinical phenotype terms— hover any for plain English:

ClubbingHP:0001217Interphalangeal joint contracture of fingerHP:0001220Diffuse palmoplantar hyperkeratosisHP:0007447Palmar hyperkeratosisHP:0010765Knuckle padHP:0032541Impaired temperature sensationHP:0010829Impaired tactile sensationHP:0010830CamptodactylyHP:0012385HypergranulosisHP:0025114
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Epidermolytic palmoplantar keratoderma.

View clinical trials →

No actively recruiting trials found for Epidermolytic palmoplantar keratoderma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Epidermolytic palmoplantar keratoderma community →

Specialists

5 foundView all specialists →
JP
Johanna H Hagman, M.D, PhD
Specialist
PI on 1 active trial
SP
Simon W Young, DDS, MD, PhD
Specialist
PI on 1 active trial
RM
Ronnie Aronson, MD
STAMFORD, CT
Specialist
PI on 2 active trials
KM
Konika P Schallen, MD
JACKSONVILLE, FL
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Epidermolytic palmoplantar keratoderma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Epidermolytic palmoplantar keratodermaForum →

No community posts yet. Be the first to share your experience with Epidermolytic palmoplantar keratoderma.

Start the conversation →

Latest news about Epidermolytic palmoplantar keratoderma

No recent news articles for Epidermolytic palmoplantar keratoderma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Epidermolytic palmoplantar keratoderma

What is Epidermolytic palmoplantar keratoderma?

Epidermolytic palmoplantar keratoderma (EPPK), also known as Vörner palmoplantar keratoderma or keratosis palmoplantaris cum degeneratione granulosa, is a hereditary skin disorder characterized by diffuse, thick, yellow hyperkeratosis (thickening of the skin) affecting the palms of the hands and soles of the feet. It is the most common form of diffuse palmoplantar keratoderma. Symptoms typically appear in the first months of life, with well-demarcated thickening of the skin on the palms and soles that may be accompanied by a red border at the margins. The thickened skin can develop painful fis

How is Epidermolytic palmoplantar keratoderma inherited?

Epidermolytic palmoplantar keratoderma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Epidermolytic palmoplantar keratoderma typically begin?

Typical onset of Epidermolytic palmoplantar keratoderma is infantile. Age of onset can vary across affected individuals.

Which specialists treat Epidermolytic palmoplantar keratoderma?

5 specialists and care centers treating Epidermolytic palmoplantar keratoderma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.